Risk factors
Indaptus Therapeutics (INDP) risk factors
Item 1A of every Indaptus Therapeutics, Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
59 risks, 9 new, 3 dropped, 7 reworded since the prior year. Mr. Lazar took control via 111.0 million convertible preferred shares representing 96.4% dilution. Patient enrollment in the Decoy20 Combination Study with BeiGene was discontinued. Cash of $8.5 million funds operations only into Q2 2026.
Filed Mar 17, 2026 - FY2024 10-K risk factors
53 risks. Clinical-stage biotechnology company focused on developing systemically-administered anti-cancer and anti-viral immunotherapy candidates, primarily Decoy20.
Filed Mar 13, 2025